KALA KALA BIO
- 6.7800
- -0.0364-0.53%
KALA BIO News
Kala Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Kala Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Kala Pharmaceuticals Price Target Cut to $21.00/Share From $22.00 by HC Wainwright & Co.
Kala Pharmaceuticals Price Target Cut to $21.00/Share From $22.00 by HC Wainwright & Co.
HC Wainwright & Co. Maintains Buy on Kala Bio, Lowers Price Target to $21
HC Wainwright & Co. analyst Yi Chen maintains Kala Bio with a Buy and lowers the price target from $22 to $21.
Kala Pharmaceuticals Price Target Maintained With a $15.00/Share by Oppenheimer
Kala Pharmaceuticals Price Target Maintained With a $15.00/Share by Oppenheimer
Oppenheimer Reiterates Outperform on Kala Bio, Maintains $15 Price Target
Oppenheimer analyst Francois Brisebois reiterates Kala Bio (NASDAQ:KALA) with a Outperform and maintains $15 price target.
Kala Pharmaceuticals GAAP EPS of -$3.18 Beats by $0.44
KALA BIO 4Q Loss/Shr $3.18 >KALA
KALA BIO 4Q Loss/Shr $3.18 >KALA
Press Release: KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update -- Advancing ongoing Phase 2b CHASE trial of KPI-012 for PCED; topline data targeted by year-end 202
KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
-- Advancing ongoing Phase 2b CHASE trial of KPI-012 for PCED; topline data targeted by year-end 2024 ---- Exploring opportunities to expand KPI-012 into additional corneal indications ---- Cash resou
KALA BIO to Present at TD Cowen 44th Annual Healthcare Conference
ARLINGTON, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovativ
KALA BIO to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
ARLINGTON, Mass., Feb. 06, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovativ
12 Health Care Stocks Moving In Tuesday's Intraday Session
GainersPHAXIAM Therapeutics (NASDAQ:PHXM) shares moved upwards by 22.1% to $5.13 during Tuesday's regular session. The market value of their outstanding shares is at $31.1 million. Travere Therapeutic
Kala Pharmaceuticals Price Target Cut to $22.00/Share From $24.00 by HC Wainwright & Co.
Kala Pharmaceuticals Price Target Cut to $22.00/Share From $24.00 by HC Wainwright & Co.
HC Wainwright & Co. Maintains Buy on Kala Bio, Lowers Price Target to $22
HC Wainwright & Co. analyst Yi Chen maintains Kala Bio (NASDAQ:KALA) with a Buy and lowers the price target from $24 to $22.
Wedbush Lowers Kala Pharmaceuticals' PT to $22 From $39, Moves US Launch Estimate for Lead Asset KPI-012; Maintains Outperform Rating
Wedbush Lowers Kala Pharmaceuticals' PT to $22 From $39, Moves US Launch Estimate for Lead Asset KPI-012; Maintains Outperform Rating
Kala Pharmaceuticals GAAP EPS of -$3.41 Misses by $1.26
Kala Pharmaceuticals Q3 EPS $(3.41) Misses $(2.15) Estimate
Kala Pharmaceuticals (NASDAQ:KALA) reported quarterly losses of $(3.41) per share which missed the analyst consensus estimate of $(2.15) by 58.6 percent. This is a 61.77 percent increase over losses o
KALA BIO Enrollment Ongoing in CHASE Phase 2b Clinical Trial of KPI-012 for PCED; Topline Data Expected in 2H 2024 >KALA
KALA BIO Enrollment Ongoing in CHASE Phase 2b Clinical Trial of KPI-012 for PCED; Topline Data Expected in 2H 2024 >KALA
KALA BIO 3Q Loss/Shr $3.41 >KALA
KALA BIO 3Q Loss/Shr $3.41 >KALA
Press Release: KALA BIO Reports Third Quarter 2023 Financial Results and Provides Corporate Update
KALA BIO Reports Third Quarter 2023 Financial Results and Provides Corporate Update -- Enrollment ongoing in CHASE Phase 2b clinical trial of KPI-012 for PCED; topline data expected in 2H 2024 -- --
Analysis
Price Target
No Data
